|  |
| --- |
| The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the Pharmaceutical Benefits Scheme (PBS) or the National Immunisation Program (NIP).The PBAC agenda consists of the following:**1 Minutes of Previous Meeting****2 Chair’s report (verbal)****3 Matters arising from the minutes** **4 Matters arising/outstanding****5 New listing applications****6 Requests for changes to listings****7 Resubmissions****8 Pricing Matters****9 Matters relating to PBS review****10 Subcommittee and Working Party reports****11 Other business****12 Correspondence****13 Further information****14 Late papers****15 Tabled papers****16 Delistings****17 Positive recommendations not accepted by applicants after 2 years**Consumers will have the opportunity to provide comments on new drug submissions (item 5), changes to listings (item 6) and resubmissions (item 7). In many circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceutical benefits listed in the Schedule fall into three broad categories:*Unrestricted benefits* – have no restrictions on their therapeutic uses; *Restricted benefits* – can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and *Authority required benefits* – Authority required benefits fall into two categories: * *Authority required benefits* require prior approval from Services Australia or the DVA (noted as Authority required)
* *Authority required (STREAMLINED) benefits* do not require prior approval from Services Australia or the DVA but require the recording of a streamlined authority code (noted as Authority required (STREAMLINED)).

Initial submissions are categorised broadly as:* *Category 1 or 2:* Submissions to list new medicines on the Schedule of Pharmaceutical Benefits or to make substantial changes to current listings are generally classified as Category 1 or 2 submissions. These submissions require presentation of an economic evaluation.
* *Category 3 or 4:* Submissions that relate to new forms of previously listed products and changes to the conditions of use e.g. change in maximum quantity/repeats or clarifying the wording of a restriction (while not altering the intended use) are considered to be Category 3 or 4 submissions. These submissions do not usually require the presentation of an economic evaluation.

Resubmissions are categorised broadly as Standard Re-entry Pathway, Early Resolution Pathway, Early Re-entry Pathway or Facilitated Resolution Pathway. Submission categories and resubmission pathways are outlined in the [Procedure Guidance](https://www.pbs.gov.au/info/industry/listing/listing-steps).  |

| **Drug Name, form(s), strength(s) and Sponsor, Submission type**(Drug name, form, strength, Trade name®, Sponsor, new listing/change to listing) | **Drug Type and Use**(What is the drug used to treat?) | **Listing requested by Sponsor / Purpose of Submission**(Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| --- | --- | --- |
| ALECTINIBCapsule 150 mgAlecensa®ROCHE PRODUCTS PTY LTD(Change to existing listing) | Non-small cell lung cancer (NSCLC) | To request a General Schedule Authority Required (Telephone/Online) listing for the adjuvant treatment in adult patients following tumour resection of anaplastic lymphoma kinase (ALK)-positive NSCLC (tumours ≥4 cm or node positive). |
| BIMEKIZUMABInjection 160 mg in 1 mL single use pre-filled penInjection 160 mg in 1 mL single use pre-filled syringeInjection 320 mg in 2 mL single use pre-filled penInjection 320 mg in 2 mL single use pre-filled syringeBimzelx®UCB AUSTRALIA PROPRIETARY LIMITED(New PBS listing) | Hidradenitis suppurativa (HS) | To request General Schedule Authority Required (Written) listings for new forms of bimekizumab, in addition to the currently listed form, for the treatment of patients with moderate to severe HS. |
| DOSTARLIMABSolution concentrate for I.V. infusion 500 mg in 10 mLJemperli®GLAXOSMITHKLINE AUSTRALIA PTY LTD(Change to existing listing) | Endometrial cancer | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for use in combination with platinum-containing chemotherapy for the treatment of primary advanced or first recurrent mismatch repair proficient endometrial cancer. |
| DURVALUMABSolution concentrate for I.V. infusion 120 mg in 2.4 mLSolution concentrate for I.V. infusion 500 mg in 10 mLImfinzi® TREMELIMUMABSolution concentrate for I.V. infusion 300 mg in 15 mLImjudo® ASTRAZENECA PTY LTD(New PBS listing) | Barcelona clinic liver cancer (BCLC)Hepatocellular carcinoma (HCC) | To request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for durvalumab in combination with tremelimumab for the first line treatment of patients with advanced (unresectable) Stage B BCLC or Stage C HCC.  |
| EMPAGLIFLOZINTablet 10 mgJardiance®BOEHRINGER INGELHEIM PTY LTD(Change to existing listing) | Chronic kidney disease (CKD) | Resubmission to request a General Schedule Authority Required (STREAMLINED) listing for the CKD incremental population. |
| ETONOGESTREL WITH ETHINYLESTRADIOLVaginal ring containing etonogestrel 11.7 mg with ethinylestradiol 2.7 mg NuvaRing®ORGANON PHARMA PTY LTD(New PBS listing) | Contraception | To request a General Schedule Restricted Benefit listing for contraception. |
| FEDRATINIBCapsule 100 mg Inrebic®BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD(New PBS listing) | Myelofibrosis (MF) | To request a General Schedule Authority Required (Telephone/Online) listing for the treatment of patients with intermediate-2/high-risk MF. |
| GUSELKUMABInjection 100 mg in 1 mL single use pre-filled penTremfya®JANSSEN-CILAG PTY LTD(Change to existing listing) | Chronic plaque psoriasis (CPP)  | To request a General Schedule Authority Required (Written) listing for the treatment of severe CPP. |
| OMALIZUMABInjection 75 mg in 0.5 mL single dose pre-filled syringeInjection 150 mg in 1 mL single dose pre-filled syringeInjection 300 mg in 2 mL single dose pre-filled syringeInjection 75 mg in 0.5 mL single dose pre-filled penInjection 150 mg in 1 mL single dose pre-filled penInjection 300 mg in 2 mL single dose pre-filled penXolair®NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED(Change to existing listing) | Chronic rhinosinusitis with nasal polyps (CRSwNP) | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the initial treatment and an Authority Required (Telephone/Online) listing for the continuing treatment of patients with CRSwNP. |
| OSIMERTINIBTablet 40 mgTablet 80 mgTagrisso®ASTRAZENECA PTY LTD(Change to existing listing) | Non-small cell lung cancer (NSCLC) | To request a General Schedule Authority Required (Telephone/Online) listing for the first line treatment of Stage IIIB (locally advanced) or Stage IV (metastatic) epidermal growth factor receptor mutation-positive (EGFRm) NSCLC in combination with pemetrexed and platinum-based chemotherapy. |
| PEGCETACOPLAN Solution for subcutaneous infusion 1,080 mg in 20 mLEmpaveli®SWEDISH ORPHAN BIOVITRUM PTY LTD(Change to existing listing) | Paroxysmal nocturnal haemoglobinuria (PNH)  | To request an amendment to the existing Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of PNH to allow initial treatment with pegcetacoplan in patients who are either treatment-naïve to complement 5 (C5) inhibitors or currently treated with a C5 inhibitor. |
| RANIBIZUMABSolution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringeSolution for intravitreal injection 2.3 mg in 0.23 mLLucentis®NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED(Change to existing listing) | Proliferative diabetic retinopathy (PDR) | To request a General Schedule Authority Required (Written) listing for the initial treatment and an Authority Required (STREAMLINED) listing for the continuing treatment of patients with PDR without diabetic macular oedema. |
| RAXTOZINAMERANI.M. injection, suspension for injection containing raxtozinameran 30 micrograms Comirnaty®PFIZER AUSTRALIA PTY LTD(New NIP listing) | Prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 | To request a National Immunisation Program listing for the prevention of coronavirus disease 2019 (COVID-19) in adults with medical risk conditions, immunocompromised patients aged 18 and older, or adults aged 60 years and over. |
| REPOTRECTINIBCapsule 40 mgCapsule 160 mg Augtyro™BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD(New PBS listing) | Non-small cell lung cancer (NSCLC) | To request a General Schedule Authority Required (Telephone/Online) listing for the treatment of locally advanced (Stage IIIB) or metastatic (Stage IV) ROS proto-oncogene 1 (ROS1)-positive NSCLC. |
| TRASTUZUMAB DERUXTECANPowder for I.V. infusion 100 mgEnhertu®ASTRAZENECA PTY LTD(Change to existing listing) | Gastric or gastroesophageal junction (G/GOJ) cancer | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (Telephone/Online) listing for the treatment of metastatic human epidermal growth factor receptor 2-positive (HER2+) G/GOJ cancer following trastuzumab therapy. |
| UBLITUXIMABSolution concentrate for I.V. infusion 150 mg in 6 mL (25 mg per mL)Briumvi®KIRCHMANN ENTERPRISES PTY LTD(New PBS listing) | Relapsing-remitting multiple sclerosis (RRMS) | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (STREAMLINED) listing for the treatment of RRMS.  |